1. Field
The present application generally relates to vascular remodeling devices and to the manner of their positioning in vessels, and, more particularly, to generally spherical remodeling devices and to the matter of their positioning at the junction of neurovascular bifurcations having an aneurysm.
2. Description of Related Art
Neurovascular or cerebral aneurysms affect about 5% of the population. Aneurysms may be located, for example, along arterial side walls (e.g., the aneurysm 10 illustrated in
In order to inhibit such herniation, tubular neck remodeling devices, for example Neuroform™, available from Boston Scientific, and Enterprise™, available from Cordis Neurovascular, may be used to keep coils or other materials within the fundus of the aneurysm and out of the vessels. Tubular remodeling devices generally consist of a braided wire or cut metallic stent or stents covering the neck of the aneurysm so that materials introduced into the fundus of the aneurysm do not herniate out of the aneurysm. As illustrated in
In some embodiments described herein, a generally spherical vascular remodeling device is provided. The device is permanently positionable at a junction of afferent and efferent vessels of a bifurcation (e.g., a neurovascular bifurcation) having an aneurysm having a fundus and a neck. Positioning may comprise deployment from a catheter and mechanical or electrolytic release from the catheter. After positioning the device at the junction, the device can lock into place across the arterial ostia and the neck of the aneurysm, substantially conforming to the shape of the junction. After positioning the device at the junction, the device acts as a scaffolding to inhibit or prevent herniation or prolapse of objects such as embolization coils and thrombi out of the neck of the aneurysm. Embolic material may be inserted in the fundus of the aneurysm before or after positioning the device. After positioning the device at the junction, the device permits perfusion of fluid (e.g., blood) to the efferent vessels. The device may have a first end, a second end substantially opposite to the first end, and a plurality of filaments extending between and coupled at the first end and the second end. Certain such devices may be football shaped, pumpkin shaped, or twisted. The device may comprise a plurality of loops (e.g., circular loops) forming a generally spherical shape, each loop comprising a self-expanding and/or a shape-memory material (e.g., comprising Nitinol, CoCr alloy, etc.). Radiopaque markers may be placed at one or both ends of the device and/or at least one of the loops or filaments may comprise a radiopaque material (e.g., platinum).
In certain embodiments, a method of treating an aneurysm at a bifurcation having an afferent vessel and efferent vessels having a junction is provided. The aneurysm has a neck and a fundus. The method comprises advancing a catheter proximate to the junction of the bifurcation. The catheter at least partially contains a generally spherical vascular remodeling device in a compressed state. The method further comprises positioning the device at the junction of the bifurcation. The device acts as a scaffolding to inhibit herniation of objects out of the nexk of the aneurysm. The device permits perfusion of fluid to the efferent vessels.
In certain embodiments, a generally spherical remodeling device comprises a first end, a second end substantially opposite to the first end, and a plurality of filaments extending between the first end and the second end and coupled at the first end and the second end. The device is configured to be positioned at a junction of a neurovascular bifurcation comprising at least one afferent vessel, efferent vessels, and an aneurysm having a neck. The device is configured to act as a scaffolding to inhibit herniation of objects out of the neck of the aneurysm. The device is configured to permit perfusion of fluid to the efferent vessels. In certain embodiments, the filaments extend continuously in a direction along the longitudinal axis from the first end to the second end, with no longitudinal reversal of direction.
In certain embodiments, a remodeling device comprises a plurality of loops forming a generally spherical shape. The device is configured to be positioned at a junction of a neurovascular bifurcation having an aneurysm. The device is configured to act as a scaffolding to inhibit matter from herniating out of the aneurysm. The device is configured to permit perfusion of blood to efferent vessels of the bifurcation.
For purposes of summarizing the invention and the advantages achieved over the prior art, certain objects and advantages of the invention are described herein. Of course, it is to be understood that not necessarily all such objects or advantages need to be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught or suggested herein without necessarily achieving other objects or advantages as may be taught or suggested herein.
All of these embodiments are intended to be within the scope of the invention herein disclosed. These and other embodiments will become readily apparent to those skilled in the art from the following detailed description having reference to the attached figures, the invention not being limited to any particular disclosed embodiment(s).
These and other features, aspects, and advantages of the present disclosure are described with reference to the drawings of certain embodiments, which are intended to illustrate certain embodiments and not to limit the invention.
Although certain embodiments and examples are described below, those of skill in the art will appreciate that the invention extends beyond the specifically disclosed embodiments and/or uses and obvious modifications and equivalents thereof. Thus, it is intended that the scope of the invention herein disclosed should not be limited by any particular embodiments described below.
In the embodiment illustrated in
In some embodiments, at least some of the loops 52 or filaments comprise a self-expanding and/or a shape-memory material (e.g., comprising Nitinol, CoCr alloy, etc.), thereby causing the device 50 to be self-expanding under certain conditions (e.g., not restrained by a catheter). In some embodiments, at least one of the loops 52 comprises a different material than others of the loops 52 (e.g., some loops 52 comprising Nitinol and some loops 52 comprising Nitinol and platinum). In some embodiments, at least one of the loops 52 comprises a radiopaque material (e.g., platinum). In certain such embodiments, an even number of loops 52 (e.g., two, four, etc.) comprises a radiopaque material (e.g., platinum). In some embodiments, at least one of the loops 52 comprises a radiopaque material (e.g., platinum) at least partially wrapped (e.g., coiled) around a self-expanding material (e.g., Nitinol). In some embodiments, at least one of the loops 52 comprises a self-expanding material with a radiopaque core (e.g., Nitinol with a platinum core) or a radiopaque coating (e.g., Nitinol coated with platinum, tantalum, etc. by physical vapor deposition, chemical vapor deposition, plating, etc.). It will be appreciated that the amount and type of radiopaque material used may depend, inter alia, on price, desired level of radiopacity, mechanical properties of the radiopaque material, and corrosion properties of the radiopaque material. In certain embodiments, the loops 52 have a substantially circular or ovoid cross section (e.g., embodiments, in which the loops 52 comprise separate wires). In some embodiments, the loops 52 have a substantially rectangular or flat cross section (e.g., embodiments, in which the loops 52 comprise uncut portions of a metallic tube). Other shapes of loops 52 and combinations of shapes of loops 52 are also possible. In certain embodiments, the plurality of loops 52 comprises between about six and about twelve loops 52. In certain embodiments, the plurality of loops 52 comprises at least about six loops 52, at least about eight loops 52, or at least about twelve loops 52. Other numbers of loops 52 are also possible.
In certain embodiments, the device 50 is configured to be positioned at a junction of a bifurcation (e.g., a neurovascular bifurcation) comprising at least one afferent vessel, efferent vessels, and an aneurysm having a fundus and a neck. For example, in some embodiments, the device 50 is suitably dimensioned to fit in a junction of a bifurcation (e.g., having a diameter between about 2 mm and about 12 mm, having a diameter between about 6 mm and about 8 mm, having a diameter less than about 12 mm, having a diameter greater than about 2 mm). For another example, in some embodiments, the device 50 is less rigid than a junction of a bifurcation (e.g., due to the number of loops 52, the material of the loops 52, the thickness of the loops 52, the spacing of the loops 52, the shape of the loops 52, combinations thereof, and the like). In certain embodiments, the device 50 is configured to act as a scaffolding to inhibit or prevent herniation or prolapse of objects (e.g., embolization coils, thrombi, etc.) out of a neck of an aneurysm. For example, in some embodiments, the loops 52 are dense enough at the neck of the aneurysm that objects cannot pass. In certain embodiments, the device 50 is configured to permit perfusion of fluid (e.g., blood) to efferent vessels of a bifurcation. For example, in some embodiments, the device 50 is substantially devoid of a covering, mesh, or other material between the loops 52, thereby allowing fluid to flow substantially unimpeded.
The device 50 comprises a plurality of perforations or cells 54 between the loops 52. In certain embodiments, a percentage of the outer surface of the device 50 covered by the loops 52 is between about 25% and about 40%. In certain embodiments, a percentage of the outer surface of the device 50 covered by the cells 54 is between about 60% and about 75%. Other porosities are also possible. In some embodiments (e.g., in embodiments in which the device 50 comprises loops 52 that form a plane and in which the intersections of the planes are substantially parallel (e.g., as illustrated in FIG. 7A)), porosity distally increases between a proximal end of the device 50 and an approximate midpoint and distally decreases between the approximate midpoint and a distal end of the device 50. In some embodiments, the device 50 further comprises one or more radiopaque markers (e.g., comprising or at least partially covering a portion of a loop 52, at a proximal end of the device 50, at a distal end of the device 50, etc.).
It will be appreciated that the term “permanently” does not mean that the device 50 is impossible to remove at a later time. In some embodiments, the device 50 may be retracted into the catheter 64 after being deployed from the catheter 64 (e.g., by pulling on the tail 53). The device 50 may then be deployed, for example at a new angle, at a new rotational position, more proximal or distal to an afferent vessel and/or an efferent vessel, etc. For example, although the device 50 expands towards an uncompressed state after deployment, the resulting shape of the device 50 at the junction of the bifurcation 60 may vary depending on the details of the deployment from the catheter 64 because the device 50 adapts to the shape of the anatomy (e.g., due to the size, shape, number, etc. of the loops 52). Once the user is satisfied with properties of the device 50 (e.g., position, tilt, rotation, shape, interaction with the vessels, etc.), the device 50 may be released as described herein.
Combinations of the steps described above are also possible. In some embodiments, the embolization coils 62 may be inserted in the fundus 22 of the aneurysm 20 after the device 50 has been deployed from the catheter 64 (e.g., using the catheter 64 to insert the embolization coils 62). In some embodiments, the embolization coils 62 may be inserted in the fundus 22 of the aneurysm 20 after the device 50 has been released from the catheter 64 (e.g., using the catheter 64 to insert the embolization coils 62).
Combinations of methods described herein are also possible. For example, a partially constructed device 50 may be positioned at the junction of the bifurcation 60, and then the device 50 may be fully constructed at the junction of the bifurcation 60. In certain such embodiments, a partially constructed device 50 having some missing loops 52 may allow better access to the aneurysm 20 for easier placement of the embolization coils 62.
The device 80 comprises a first or distal end 81 and a second or proximal end 82 substantially opposite the first end 81. The device 80 further comprises a plurality of filaments 84 extending between the first end 81 and the second end 82. The first end 81 extends outwardly and the second end 82 extends outwardly to form a generally spherical (e.g., oval or oblong) shape similar to a football, a rugby ball, or a watermelon. In certain embodiments, the filaments 84 are coupled at the first end 81 and/or the second end 82 (e.g., by adhering, welding, soldering, combinations thereof, and the like). In the embodiment illustrated in
In certain embodiments, the device 80 is configured to be positioned at a junction of a bifurcation (e.g., a neurovascular bifurcation) comprising at least one afferent vessel, efferent vessels, and an aneurysm having a fundus and a neck. For example, in some embodiments, the device 80 is suitably dimensioned to fit in a junction of a bifurcation (e.g., having a diameter between about 2 mm and about 12 mm, having a diameter between about 6 mm and about 8 mm, having a diameter less than about 12 mm, having a diameter greater than about 2 mm). For another example, in some embodiments, the device 80 is less rigid than a junction of a bifurcation (e.g., due to the number of filaments 84, the material of the filaments 84, the thickness of the filaments 84, the spacing of the filaments 84, the shape of the filaments 84, combinations thereof, and the like). In certain embodiments, the device 80 is configured to act as a scaffolding to inhibit or prevent herniation or prolapse of objects (e.g., embolization coils, thrombi, etc.) out of a neck of an aneurysm. For example, in some embodiments, the filaments 84 are dense enough at the neck of the aneurysm that objects cannot pass. In certain embodiments, the device 80 is configured to permit perfusion of fluid (e.g., blood) to efferent vessels of a bifurcation. For example, in some embodiments, the device 80 is substantially devoid of a covering, mesh, or other material between the filaments 84, thereby allowing fluid to flow substantially unimpeded.
In some embodiments, at least one of the filaments 84 comprises a self-expanding and/or a shape-memory material (e.g., comprising Nitinol, CoCr alloy, etc.), thereby causing the device 80 to be self-expanding under certain conditions (e.g., not restrained by a catheter). In some embodiments, at least one of the filaments 84 comprises a different material than others of the filaments 84 (e.g., some filaments 84 comprising Nitinol and some filaments 84 comprising Nitinol and platinum). In some embodiments, at least one of the filaments 84 comprises a radiopaque material (e.g., platinum). In certain such embodiments, an even number of filaments 84 (e.g., two, four, etc.) comprises a radiopaque material (e.g., platinum). In some embodiments, at least one of the filaments 84 comprises a radiopaque material (e.g., platinum) at least partially wrapped (e.g., coiled) around a self-expanding material (e.g., Nitinol). In some embodiments, at least one of the filaments 84 comprises a self-expanding material with a radiopaque core (e.g., Nitinol with a platinum core) or a radiopaque coating (e.g., Nitinol coated with platinum, tantalum, etc. by physical vapor deposition, chemical vapor deposition, plating, etc.). It will be appreciated that the amount and type of radiopaque material used may depend, inter alia, on price, desired level of radiopacity, mechanical properties of the radiopaque material, and corrosion properties of the radiopaque material. In certain embodiments, the filaments 84 have a substantially circular or ovoid cross section (e.g., embodiments, in which the filaments 84 comprise separate wires). In some embodiments, the filaments 84 have a substantially rectangular or flat cross section (e.g., embodiments, in which the filaments 84 comprise uncut portions of a metallic tube, as described below). Other shapes of filaments 84 and combinations of shapes of filaments 84 are also possible. In certain embodiments, the plurality of filaments 84 comprises between about six and about twelve filaments 84. In certain embodiments, the plurality of filaments 84 comprises at least about six filaments 84, at least about eight filaments 84, or at least about twelve filaments 84. Other numbers of filaments 84 are also possible.
The device 80 comprises a plurality of perforations or cells 86 between the filaments 84. In certain embodiments, a percentage of the outer surface of the device 80 covered by the filaments 84 is between about 25% and about 40%. In certain embodiments, a percentage of the outer surface of the device 80 covered by the cells 86 is between about 60% and about 75%. Other porosities are also possible. In some embodiments, porosity distally increases between the second end 82 and an approximate midpoint (e.g., approximately at the line A-A in
100%×[1−(≈0.5 mm/filament×10 filaments/≈25 mm)]≈80%
and the porosity at the cross-section B-B would be about 33% with an example circumference of about 7.5 mm:
100%×[1−(≈0.5 mm/filament×10 filaments/≈7.5 mm)]≈33%.
High porosity proximate to a midpoint of the device 80 may provide good fluid flow to efferent vessels. Low porosity proximate to the first end 81 of the device 80 may provide good scaffolding properties.
In some embodiments, the device 80 further comprises a radiopaque marker 88 proximate to the first end 81 and/or a radiopaque marker 89 proximate to the second end 82. In certain embodiments, the radiopaque marker 88 may extend at least partially into the aneurysm 20 when the device 80 is positioned at the junction of a bifurcation. In some embodiments, the radiopaque markers 88, 89 may comprise a sleeve positioned or wrapped around the filaments 84, thereby coupling the filaments 84. The radiopaque markers 88, 89 may aid in positioning the device 80 at the junction of a bifurcation.
In some embodiments, the device 80 further comprises a covering (e.g., comprising a porous or non-porous polymer) proximate to the first end 81. In some embodiments, the covering improves the scaffolding properties of the device 80 by reducing the porosity at the first end 81, thereby further inhibiting the herniation or prolapse of embolic material from the aneurysm 20. In certain embodiments, the covering may be attached to the device 80 by sewing the covering from a pre-formed thin film. In certain embodiments, the covering may be mechanically attached (e.g., wrapped around, looped through, etc.) the filaments 84. In certain embodiments, the covering may be deposited (e.g., via physical vapor deposition, chemical vapor deposition, etc.) on the filaments 84. Other portions of the device 80 may also comprise a covering.
It will be appreciated that the term “permanently” does not mean that the device 80 is impossible to remove at a later time. In some embodiments, the device 80 may be retracted into the catheter 92 after being deployed from the catheter 92 (e.g., by pulling on the tail 83). The device 80 may then be deployed, for example at a new angle, at a new rotational position, more proximal or distal to an afferent vessel and/or an efferent vessel, etc. For example, although the device 80 expands towards an uncompressed state after deployment, the resulting shape of the device 80 at the junction of the bifurcation 60 may vary depending on the details of the deployment from the catheter 92 because the device 80 adapts to the shape of the anatomy (e.g., due to the size, shape, number, etc. of the loops 82). Once the user is satisfied with properties of the device 80 (e.g., position, tilt, rotation, shape, interaction with the vessels, etc.), the device 80 may be released as described herein.
In the embodiment illustrated in
The device 110 comprises a first or distal end 111 and a second or proximal end 112 substantially opposite the first end 111. The device 110 further comprises a plurality of filaments 114 extending between the first end 111 and the second end 112. In the device 110 illustrated in
In certain embodiments, the device 110 is configured to be positioned at a junction of a bifurcation (e.g., a neurovascular bifurcation) comprising at least one afferent vessel, efferent vessels, and an aneurysm having a fundus and a neck. For example, in some embodiments, the device 110 is suitably dimensioned to fit in a junction of a bifurcation (e.g., having a diameter between about 2 mm and about 12 mm, having a diameter between about 6 mm and about 8 mm, having a diameter less than about 12 mm, having a diameter greater than about 2 mm). For another example, in some embodiments, the device 110 is less rigid than a junction of a bifurcation (e.g., due to the number of filaments 114, the material of the filaments 114, the thickness of the filaments 114, the spacing of the filaments 114, the shape of the filaments 114, combinations thereof, and the like). In certain embodiments, the device 110 is configured to act as a scaffolding to inhibit or prevent herniation or prolapse of objects (e.g., embolization coils, thrombi, etc.) out of a neck of an aneurysm. For example, in some embodiments, the filaments 114 are dense enough at the neck of the aneurysm that objects cannot pass. In certain embodiments, the device 110 is configured to permit perfusion of fluid (e.g., blood) to efferent vessels of a bifurcation. For example, in some embodiments, the device 110 is substantially devoid of a covering, mesh, or other material between the filaments 114, thereby allowing fluid to flow substantially unimpeded.
In some embodiments, at least one of the filaments 114 comprises a self-expanding and/or a shape-memory material (e.g., comprising Nitinol, CoCr alloy, etc.), thereby causing the device 110 to be self-expanding under certain conditions (e.g., not restrained by a catheter). In some embodiments, at least one of the filaments 114 comprises a different material than others of the filaments 114 (e.g., some filaments 114 comprising Nitinol and some filaments 114 comprising Nitinol and platinum). In some embodiments, at least one of the filaments 114 comprises a radiopaque material (e.g., platinum). In certain such embodiments, an even number of filaments 84 (e.g., two, four, etc.) comprises a radiopaque material (e.g., platinum). In some embodiments, at least one of the filaments 84 comprises a radiopaque material (e.g., platinum) at least partially wrapped (e.g., coiled) around a self-expanding material (e.g., Nitinol). In some embodiments, at least one of the filaments 84 comprises a self-expanding material with a radiopaque core (e.g., Nitinol with a platinum core) or a radiopaque coating (e.g., Nitinol coated with platinum, tantalum, etc. by physical vapor deposition, chemical vapor deposition, plating, etc.). It will be appreciated that the amount and type of radiopaque material used may depend, inter alia, on price, desired level of radiopacity, mechanical properties of the radiopaque material, and corrosion properties of the radiopaque material. In certain embodiments, the filaments 114 have a substantially circular or ovoid cross section section (e.g., embodiments, in which the filaments 84 comprise separate wires). In some embodiments, the filaments 114 have a substantially rectangular or flat cross section (e.g., embodiments, in which the filaments 84 comprise uncut portions of a metallic tube). Other shapes of filaments 114 and combinations of shapes of filaments 114 are also possible. In certain embodiments, the plurality of filaments 84 comprises between about six and about twelve filaments 114. In certain embodiments, the plurality of filaments 114 comprises at least about six filaments 114, at least about eight filaments 114, or at least about twelve filaments 114. Other numbers of filaments 114 are also possible.
The device 110 comprises a plurality of perforations or cells 116 between the filaments 114. In certain embodiments, a percentage of the outer surface of the device 110 covered by the filaments 114 is between about 25% and about 40%. In certain embodiments, a percentage of the outer surface of the device 110 covered by the cells 116 is between about 60% and about 75%. Other porosities are also possible. In some embodiments, porosity distally increases between the second end 112 and an approximate midpoint and distally decreases between the approximate midpoint and the first end 111.
In some embodiments, the device 110 further comprises a radiopaque marker 118 proximate to the first end 111 and/or a radiopaque marker 119 proximate to the second end 112. In certain embodiments, the radiopaque marker 118 may extend at least partially into the aneurysm 20 when the device 110 is positioned at the junction of a bifurcation. In some embodiments, the radiopaque markers 118, 119 may comprise a sleeve situated or wrapped around the filaments 114, thereby coupling the filaments 114. The radiopaque markers 118, 119 may aid in positioning the device 110 at the junction of a bifurcation.
In some embodiments, the device 110 further comprises a covering (e.g., comprising a porous or non-porous polymer) proximate to the first end 111. In some embodiments, the covering improves the scaffolding properties of the device 110 by reducing the porosity at the first end 111, thereby further inhibiting the herniation or prolapse of embolic material from the aneurysm 20. In certain embodiments, the covering may be attached to the device 110 by sewing the covering from a pre-formed thin film. In certain embodiments, the covering may be mechanically attached (e.g., wrapped around, looped through, etc.) the filaments 114. In certain embodiments, the covering may be deposited (e.g., via physical vapor deposition, chemical vapor deposition, etc.) on the filaments 114. Other portions of the device 110 may also comprise a covering.
As described above, the term “bifurcation” described herein is not limited to the particular vasculature illustrated in
The device 130 comprises a first or distal end 131 and a second or proximal end 132 substantially opposite the first end 131. The device 130 further comprises a plurality of filaments 134 extending between the first end 131 and the second end 132. In the device 130 illustrated in
In certain embodiments, the device 130 is configured to be positioned at a junction of a bifurcation (e.g., a neurovascular bifurcation) comprising at least one afferent vessel, efferent vessels, and an aneurysm having a fundus and a neck. For example, in some embodiments, the device 130 is suitably dimensioned to fit in a junction of a bifurcation (e.g., having a diameter between about 2 mm and about 12 mm, having a diameter between about 6 mm and about 8 mm, having a diameter less than about 12 mm, having a diameter greater than about 2 mm). For another example, in some embodiments, the device 130 is less rigid than a junction of a bifurcation (e.g., due to the number of filaments 134, the material of the filaments 134, the thickness of the filaments 134, the spacing of the filaments 134, the shape of the filaments 134, combinations thereof, and the like). In certain embodiments, the device 130 is configured to act as a scaffolding to inhibit or prevent herniation or prolapse of objects (e.g., embolization coils, thrombi, etc.) out of a neck of an aneurysm. For example, in some embodiments, the filaments 134 are dense enough at the neck of the aneurysm that objects cannot pass. In certain embodiments, the device 130 is configured to permit perfusion of fluid (e.g., blood) to efferent vessels of a bifurcation. For example, in some embodiments, the device 130 is substantially devoid of a covering, mesh, or other material between the filaments 134, thereby allowing fluid to flow substantially unimpeded.
In some embodiments, at least one of the filaments 134 comprises a self-expanding and/or a shape-memory material (e.g., comprising Nitinol, CoCr alloy, etc.), thereby causing the device 130 to be self-expanding under certain conditions (e.g., not restrained by a catheter). In some embodiments, at least one of the filaments 134 comprises a different material than others of the filaments 134 (e.g., some filaments 134 comprising Nitinol and some filaments 134 comprising Nitinol and platinum). In some embodiments, at least one of the filaments 134 comprises a radiopaque material (e.g., platinum). In certain such embodiments, an even number of filaments 84 (e.g., two, four, etc.) comprises a radiopaque material (e.g., platinum). In some embodiments, at least one of the filaments 84 comprises a radiopaque material (e.g., platinum) at least partially wrapped (e.g., coiled) around a self-expanding material (e.g., Nitinol). In some embodiments, at least one of the filaments 84 comprises a self-expanding material with a radiopaque core (e.g., Nitinol with a platinum core) or a radiopaque coating (e.g., Nitinol coated with platinum, tantalum, etc. by physical vapor deposition, chemical vapor deposition, plating, etc.). It will be appreciated that the amount and type of radiopaque material used may depend, inter alia, on price, desired level of radiopacity, mechanical properties of the radiopaque material, and corrosion properties of the radiopaque material. In certain embodiments, the filaments 134 have a substantially circular or ovoid cross section (e.g., embodiments, in which the filaments 84 comprise separate wires). In some embodiments, the filaments 134 have a substantially rectangular or flat cross section (e.g., embodiments, in which the filaments 84 comprise uncut portions of a metallic tube). Other shapes of filaments 134 and combinations of shapes of filaments 134 are also possible. In certain embodiments, the plurality of filaments 84 comprises between about six and about twelve filaments 134. In certain embodiments, the plurality of filaments 134 comprises at least about six filaments 134, at least about eight filaments 134, or at least about twelve filaments 134. Other numbers of filaments 134 are also possible.
The device 130 comprises a plurality of perforations or cells 136 between the filaments 134. In certain embodiments, a percentage of the outer surface of the device 130 covered by the filaments 134 is between about 25% and about 40%. In certain embodiments, a percentage of the outer surface of the device 130 covered by the cells 136 is between about 60% and about 75%. Other porosities are also possible. In some embodiments, porosity distally increases between the second end 132 and an approximate midpoint and distally decreases between the approximate midpoint and the first end 131.
In some embodiments, the device 130 further comprises a radiopaque marker 138 proximate to the first end 131 and/or a radiopaque marker 139 proximate to the second end 132. In certain embodiments, the radiopaque marker 138 may extend at least partially into the aneurysm 20 when the device 130 is positioned at the junction of a bifurcation. In some embodiments, the radiopaque markers 138, 139 may comprise a sleeve situated or wrapped around the filaments 134, thereby coupling the filaments 134. The radiopaque markers 138, 139 may aid in positioning the device 130 at the junction of a bifurcation.
In some embodiments, the device 130 further comprises a covering (e.g., comprising a porous or non-porous polymer) proximate to the first end 131. In some embodiments, the covering improves the scaffolding properties of the device 130 by reducing the porosity at the first end 131, thereby further inhibiting the herniation or prolapse of embolic material from the aneurysm 20. In certain embodiments, the covering may be attached to the device 130 by sewing the covering from a pre-formed thin film. In certain embodiments, the covering may be mechanically attached (e.g., wrapped around, looped through, etc.) the filaments 134. In certain embodiments, the covering may be deposited (e.g., via physical vapor deposition, chemical vapor deposition, etc.) on the filaments 134. Other portions of the device 130 may also comprise a covering.
The device 130 may be positioned and retracted as described, for example, by performing a method similar to the method described with respect to
In some embodiments, the device 140 further comprises a radiopaque marker 148 proximate to the first end 141 and/or a radiopaque marker 149 proximate to the second end 142. In certain embodiments, the radiopaque marker 148 may extend at least partially into the aneurysm 20 when the device 140 is positioned at the junction of a bifurcation. In some embodiments, the radiopaque markers 148, 149 may be integral with the device by being defined by the cut tube. The radiopaque markers 148, 149 may aid in positioning the device 140 at the junction of a bifurcation.
The cut tube can then be expanded into a generally spherical shape through shape setting using a heat treatment process. The shape setting process may include several steps comprising of successively increasing diameters of generally spherical shapes using appropriate tooling to stretch and confine the cut tube into a new shape while heat treating it. At the end of the each heat treatment step, the cut tube assumes the shape in which it was confined during the heat treatment process. This process is then repeated to form a slightly larger size and a shape closer to the end product. The final shape (e.g., a football shape similar to the device 80) and size may obtained by several such steps. Other devices described herein (e.g., the devices 50, 110, 130) may also be formed using cut a metallic tube that is reshaped after being cut, although it will be appreciated that the pattern of the initial cut may be different, such that details about possible materials, dimensions, porosities, deployment methods, possibly coverings, etc. are not provided.
Certain devices described herein may be advantageously used to treat aneurysms having a neck ratio (a ratio of fundus width to neck width) greater than about 2 to 1 and/or a neck width greater than about 4 mm. In treatment of such aneurysms, embolization coils may be prone to herniating into parent vessels because the size and/or shape of the aneurysm is not conducive to maintaining the coils in their inserted locus. In certain such embodiments, embolization coils are inserted in the fundus of the aneurysm after positioning a generally spherical device so that the embolization coils do not have an opportunity to herniate. It will be appreciated that certain devices described herein may also be used to treat aneurysms having a neck ratio less than about 2 to 1 and/or a neck width less than about 4 mm. In certain such embodiments, embolization coils are inserted in the fundus of the aneurysm before positioning a generally spherical device.
Certain devices described herein may advantageously be a single generally spherical device placed at a junction of a bifurcation rather than a plurality of tubular bifurcations. Certain such devices can span a neck of an aneurysm as well as arterial ostia. Positioning such devices may be less complicated, thereby reducing risks associated with, for example, than ensuring that a tubular device is properly anchored in an afferent vessel and in an efferent vessel.
In some embodiments in which embolic material was previously inserted in an aneurysm but has herniated, certain devices described herein may be used as a “rescue device” to push the herniated material back into the aneurysm and to act as a scaffolding to inhibit or prevent further herniation or prolapse of the embolic material. In certain such embodiments, deployment of such devices may advantageously avoid traversal of the junction comprising the herniated material by wires or a catheter (e.g., there is no need to traverse wires or a catheter past the junction into an efferent vessel for positioning of the device as is generally needed to position tubular devices such as the devices 42, 44 illustrated in
Although this invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while several variations of the embodiments of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. It should be understood that various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to form varying modes of the embodiments of the disclosed invention. Thus, it is intended that the scope of the invention herein disclosed should not be limited by the particular embodiments described above.
This application claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/082,579, filed Jul. 22, 2008, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3108593 | Glassman | Oct 1963 | A |
4425908 | Simon | Jan 1984 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4655771 | Wallsten | Apr 1987 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4921484 | Hillstead | May 1990 | A |
4998539 | Delsanti | Mar 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5104404 | Wolff | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5222971 | Willard et al. | Jun 1993 | A |
5250071 | Palermo | Oct 1993 | A |
5334210 | Gianturco | Aug 1994 | A |
5378239 | Termin et al. | Jan 1995 | A |
5405379 | Lane | Apr 1995 | A |
5425984 | Kennedy et al. | Jun 1995 | A |
5484444 | Braunschweiler et al. | Jan 1996 | A |
5499981 | Kordis | Mar 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5624461 | Mariant | Apr 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5690671 | McGurk et al. | Nov 1997 | A |
5702419 | Berry et al. | Dec 1997 | A |
5713907 | Hogendijk et al. | Feb 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5728906 | Eguchi et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5741333 | Frid | Apr 1998 | A |
5749891 | Ken et al. | May 1998 | A |
5749919 | Blanc | May 1998 | A |
5749920 | Quiachon et al. | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5814062 | Sepetka et al. | Sep 1998 | A |
5830230 | Berryman et al. | Nov 1998 | A |
5846261 | Kotula et al. | Dec 1998 | A |
5855578 | Guglielmi et al. | Jan 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5911731 | Pham et al. | Jun 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5925060 | Forber | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5935362 | Petrick | Aug 1999 | A |
5941249 | Maynard | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5957948 | Mariant | Sep 1999 | A |
5980554 | Lenker et al. | Nov 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6033423 | Ken et al. | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6059813 | Vrba et al. | May 2000 | A |
6063070 | Eder | May 2000 | A |
6063104 | Villar et al. | May 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096034 | Kupiecki et al. | Aug 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099526 | Whayne et al. | Aug 2000 | A |
6106530 | Harada | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6139564 | Teoh | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6168615 | Ken et al. | Jan 2001 | B1 |
6168618 | Frantzen | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6183495 | Lenker et al. | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6221086 | Forber | Apr 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6280412 | Pederson, Jr. et al. | Aug 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6309367 | Boock | Oct 2001 | B1 |
6322576 | Wallace et al. | Nov 2001 | B1 |
6325820 | Khosravi et al. | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6342068 | Thompson | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6346117 | Greenhalgh | Feb 2002 | B1 |
6350270 | Roue | Feb 2002 | B1 |
6361558 | Hieshima et al. | Mar 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6530934 | Jacobsen et al. | Mar 2003 | B1 |
6544278 | Vrba et al. | Apr 2003 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6569179 | Teoh et al. | May 2003 | B2 |
6579302 | Duerig et al. | Jun 2003 | B2 |
6579303 | Amplatz | Jun 2003 | B2 |
6585748 | Jeffree | Jul 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589256 | Forber | Jul 2003 | B2 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592605 | Lenker et al. | Jul 2003 | B2 |
6599308 | Amplatz | Jul 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6605111 | Bose et al. | Aug 2003 | B2 |
6607551 | Sullivan et al. | Aug 2003 | B1 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6635069 | Teoh et al. | Oct 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6666882 | Bose et al. | Dec 2003 | B1 |
6666883 | Seguin et al. | Dec 2003 | B1 |
6669717 | Marotta et al. | Dec 2003 | B2 |
6669721 | Bose et al. | Dec 2003 | B1 |
6676696 | Marotta et al. | Jan 2004 | B1 |
6682505 | Bates et al. | Jan 2004 | B2 |
6682546 | Amplatz | Jan 2004 | B2 |
6689150 | VanTassel et al. | Feb 2004 | B1 |
6689486 | Ho et al. | Feb 2004 | B2 |
6695876 | Marotta et al. | Feb 2004 | B1 |
6699274 | Stinson | Mar 2004 | B2 |
6712835 | Mazzocchi et al. | Mar 2004 | B2 |
6723112 | Ho et al. | Apr 2004 | B2 |
6723116 | Taheri | Apr 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6746468 | Spetka et al. | Jun 2004 | B1 |
6746890 | Gupta et al. | Jun 2004 | B2 |
6780196 | Chin et al. | Aug 2004 | B2 |
6792979 | Konya et al. | Sep 2004 | B2 |
6797083 | Peterson | Sep 2004 | B2 |
6802851 | Jones et al. | Oct 2004 | B2 |
RE38653 | Igaki et al. | Nov 2004 | E |
6811560 | Jones et al. | Nov 2004 | B2 |
6855153 | Saadat | Feb 2005 | B2 |
6855154 | Abdel-Gawwad | Feb 2005 | B2 |
RE38711 | Igaki et al. | Mar 2005 | E |
6860893 | Wallace et al. | Mar 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6949103 | Mazzocchi et al. | Sep 2005 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6979341 | Scribner et al. | Dec 2005 | B2 |
6989019 | Mazzocchi et al. | Jan 2006 | B2 |
6994092 | van der Burg et al. | Feb 2006 | B2 |
6994717 | Konya et al. | Feb 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7029487 | Greene, Jr. et al. | Apr 2006 | B2 |
7033375 | Mazzocchi et al. | Apr 2006 | B2 |
7048752 | Mazzocchi et al. | May 2006 | B2 |
7063679 | Maguire et al. | Jun 2006 | B2 |
7070607 | Murayama et al. | Jul 2006 | B2 |
7070609 | West | Jul 2006 | B2 |
7083632 | Avellanet et al. | Aug 2006 | B2 |
7128073 | van der Burg et al. | Oct 2006 | B1 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7169177 | Obara | Jan 2007 | B2 |
7195636 | Avellanet et al. | Mar 2007 | B2 |
7211109 | Thompson | May 2007 | B2 |
7229461 | Chin et al. | Jun 2007 | B2 |
7232461 | Ramer | Jun 2007 | B2 |
7244267 | Huter et al. | Jul 2007 | B2 |
7261720 | Stevens et al. | Aug 2007 | B2 |
7303571 | Makower et al. | Dec 2007 | B2 |
7306622 | Jones et al. | Dec 2007 | B2 |
7331980 | Dubrul et al. | Feb 2008 | B2 |
7367985 | Mazzocchi et al. | May 2008 | B2 |
7367986 | Mazzocchi et al. | May 2008 | B2 |
7371250 | Mazzocchi et al. | May 2008 | B2 |
7393358 | Malewicz | Jul 2008 | B2 |
7404820 | Mazzocchi et al. | Jul 2008 | B2 |
7410482 | Murphy et al. | Aug 2008 | B2 |
7410492 | Mazzocchi et al. | Aug 2008 | B2 |
7413622 | Peterson | Aug 2008 | B2 |
7419503 | Pulnev et al. | Sep 2008 | B2 |
7442200 | Mazzocchi et al. | Oct 2008 | B2 |
7485088 | Murphy et al. | Feb 2009 | B2 |
7556635 | Mazzocchi et al. | Jul 2009 | B2 |
7566338 | Mazzocchi et al. | Jul 2009 | B2 |
7569066 | Gerberding et al. | Aug 2009 | B2 |
7572273 | Mazzocchi et al. | Aug 2009 | B2 |
7572288 | Cox | Aug 2009 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7608088 | Jones et al. | Oct 2009 | B2 |
7621928 | Thramann et al. | Nov 2009 | B2 |
7632296 | Malewicz | Dec 2009 | B2 |
7670355 | Mazzocchi et al. | Mar 2010 | B2 |
7670356 | Mazzocchi et al. | Mar 2010 | B2 |
7678130 | Mazzocchi et al. | Mar 2010 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7695488 | Berenstein et al. | Apr 2010 | B2 |
7699056 | Tran et al. | Apr 2010 | B2 |
7727189 | VanTassel et al. | Jun 2010 | B2 |
7744583 | Seifert et al. | Jun 2010 | B2 |
7744652 | Morsi | Jun 2010 | B2 |
7763011 | Ortiz et al. | Jul 2010 | B2 |
7828815 | Mazzocchi et al. | Nov 2010 | B2 |
7828816 | Mazzocchi et al. | Nov 2010 | B2 |
7906066 | Wilson et al. | Mar 2011 | B2 |
7922732 | Mazzocchi et al. | Apr 2011 | B2 |
7955343 | Makower et al. | Jun 2011 | B2 |
7972359 | Kreidler | Jul 2011 | B2 |
7993364 | Morsi | Aug 2011 | B2 |
RE42758 | Ken et al. | Sep 2011 | E |
8016869 | Nikolchev | Sep 2011 | B2 |
8016872 | Parker | Sep 2011 | B2 |
8062379 | Morsi | Nov 2011 | B2 |
8075585 | Lee et al. | Dec 2011 | B2 |
8142456 | Rosqueta et al. | Mar 2012 | B2 |
8202280 | Richter | Jun 2012 | B2 |
8221445 | van Tassel et al. | Jul 2012 | B2 |
8261648 | Marchand et al. | Sep 2012 | B1 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
8430012 | Marchand et al. | Apr 2013 | B1 |
8454681 | Holman et al. | Jun 2013 | B2 |
20010000797 | Mazzocchi | May 2001 | A1 |
20010012949 | Forber | Aug 2001 | A1 |
20010051822 | Stack et al. | Dec 2001 | A1 |
20020013599 | Limon et al. | Jan 2002 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020042628 | Chin et al. | Apr 2002 | A1 |
20020062091 | Jacobsen et al. | May 2002 | A1 |
20020165572 | Saadat | Nov 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030171739 | Murphy et al. | Sep 2003 | A1 |
20030171770 | Kusleika et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030195553 | Wallace et al. | Oct 2003 | A1 |
20030199913 | Dubrul et al. | Oct 2003 | A1 |
20030199919 | Palmer et al. | Oct 2003 | A1 |
20040015224 | Armstrong et al. | Jan 2004 | A1 |
20040034386 | Fulton et al. | Feb 2004 | A1 |
20040044391 | Porter | Mar 2004 | A1 |
20040098027 | Teoh et al. | May 2004 | A1 |
20040098030 | Makower et al. | May 2004 | A1 |
20040106945 | Thramann et al. | Jun 2004 | A1 |
20040106977 | Sullivan et al. | Jun 2004 | A1 |
20040111112 | Hoffmann | Jun 2004 | A1 |
20040122467 | VanTassel et al. | Jun 2004 | A1 |
20040122468 | Yodfat et al. | Jun 2004 | A1 |
20040143239 | Zhou et al. | Jul 2004 | A1 |
20040143286 | Johnson et al. | Jul 2004 | A1 |
20040153119 | Kusleika et al. | Aug 2004 | A1 |
20040162606 | Thompson | Aug 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040181253 | Sepetka et al. | Sep 2004 | A1 |
20040186562 | Cox | Sep 2004 | A1 |
20040193206 | Gerberding et al. | Sep 2004 | A1 |
20040215229 | Coyle | Oct 2004 | A1 |
20040215332 | Frid | Oct 2004 | A1 |
20040249408 | Murphy et al. | Dec 2004 | A1 |
20040267346 | Shelso | Dec 2004 | A1 |
20050010281 | Yodfat et al. | Jan 2005 | A1 |
20050021077 | Chin et al. | Jan 2005 | A1 |
20050033408 | Jones et al. | Feb 2005 | A1 |
20050033409 | Burke et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050060017 | Fischell et al. | Mar 2005 | A1 |
20050096728 | Ramer | May 2005 | A1 |
20050096732 | Marotta et al. | May 2005 | A1 |
20050107823 | Leone et al. | May 2005 | A1 |
20050131443 | Abdel-Gawwad | Jun 2005 | A1 |
20050228434 | Amplatz et al. | Oct 2005 | A1 |
20050267568 | Berez et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050288763 | Andreas et al. | Dec 2005 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060074475 | Gumm | Apr 2006 | A1 |
20060106421 | Teoh | May 2006 | A1 |
20060116713 | Sepetka et al. | Jun 2006 | A1 |
20060116714 | Sepetka et al. | Jun 2006 | A1 |
20060155323 | Porter et al. | Jul 2006 | A1 |
20060167494 | Suddaby | Jul 2006 | A1 |
20060190070 | Dieck et al. | Aug 2006 | A1 |
20060190076 | Taheri | Aug 2006 | A1 |
20060200221 | Malewicz | Sep 2006 | A1 |
20060206199 | Churchwell et al. | Sep 2006 | A1 |
20060206200 | Garcia et al. | Sep 2006 | A1 |
20060235464 | Avellanet et al. | Oct 2006 | A1 |
20060235501 | Igaki | Oct 2006 | A1 |
20060241690 | Amplatz et al. | Oct 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060264905 | Eskridge et al. | Nov 2006 | A1 |
20060264907 | Eskridge et al. | Nov 2006 | A1 |
20060271149 | Berez et al. | Nov 2006 | A1 |
20060271153 | Garcia et al. | Nov 2006 | A1 |
20060276827 | Mitelberg et al. | Dec 2006 | A1 |
20060282152 | Beyerlein et al. | Dec 2006 | A1 |
20060292206 | Kim et al. | Dec 2006 | A1 |
20060293744 | Peckham et al. | Dec 2006 | A1 |
20070005125 | Berenstein et al. | Jan 2007 | A1 |
20070016243 | Ramaiah et al. | Jan 2007 | A1 |
20070021816 | Rudin | Jan 2007 | A1 |
20070050017 | Sims et al. | Mar 2007 | A1 |
20070088387 | Eskridge et al. | Apr 2007 | A1 |
20070093889 | Wu et al. | Apr 2007 | A1 |
20070100415 | Licata et al. | May 2007 | A1 |
20070106311 | Wallace et al. | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070150045 | Ferrera | Jun 2007 | A1 |
20070162104 | Frid | Jul 2007 | A1 |
20070173928 | Morsi | Jul 2007 | A1 |
20070191884 | Eskridge et al. | Aug 2007 | A1 |
20070191924 | Rudakov | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070203567 | Levy | Aug 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070221230 | Thompson et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070225794 | Thramann et al. | Sep 2007 | A1 |
20070233244 | Lopez et al. | Oct 2007 | A1 |
20070239261 | Bose et al. | Oct 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288083 | Hines | Dec 2007 | A1 |
20080009934 | Schneider et al. | Jan 2008 | A1 |
20080021535 | Leopold et al. | Jan 2008 | A1 |
20080039933 | Yodfat et al. | Feb 2008 | A1 |
20080045996 | Makower et al. | Feb 2008 | A1 |
20080045997 | Balgobin et al. | Feb 2008 | A1 |
20080051705 | Von Oepen et al. | Feb 2008 | A1 |
20080058856 | Ramaiah et al. | Mar 2008 | A1 |
20080065141 | Holman et al. | Mar 2008 | A1 |
20080065145 | Carpenter | Mar 2008 | A1 |
20080097495 | Feller, III et al. | Apr 2008 | A1 |
20080109063 | Hancock et al. | May 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080114436 | Dieck et al. | May 2008 | A1 |
20080114439 | Ramaiah et al. | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080125806 | Mazzocchi et al. | May 2008 | A1 |
20080125848 | Kusleika et al. | May 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20080140177 | Hines | Jun 2008 | A1 |
20080154286 | Abbott et al. | Jun 2008 | A1 |
20080195139 | Donald et al. | Aug 2008 | A1 |
20080219533 | Grigorescu | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080243226 | Fernandez et al. | Oct 2008 | A1 |
20080249562 | Cahill | Oct 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20080319533 | Lehe | Dec 2008 | A1 |
20090025820 | Adams | Jan 2009 | A1 |
20090069806 | De La Mora Levy et al. | Mar 2009 | A1 |
20090082803 | Adams et al. | Mar 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090112251 | Qian et al. | Apr 2009 | A1 |
20090118811 | Moloney | May 2009 | A1 |
20090143849 | Ozawa et al. | Jun 2009 | A1 |
20090143851 | Paul, Jr. | Jun 2009 | A1 |
20090198315 | Boudjemline | Aug 2009 | A1 |
20090210047 | Amplatz et al. | Aug 2009 | A1 |
20090216307 | Kaufmann et al. | Aug 2009 | A1 |
20090228029 | Lee | Sep 2009 | A1 |
20090228093 | Taylor et al. | Sep 2009 | A1 |
20090259202 | Leeflang et al. | Oct 2009 | A1 |
20090264914 | Riina et al. | Oct 2009 | A1 |
20090275974 | Marchand et al. | Nov 2009 | A1 |
20090287291 | Becking et al. | Nov 2009 | A1 |
20090287294 | Rosqueta et al. | Nov 2009 | A1 |
20090287297 | Cox | Nov 2009 | A1 |
20090318941 | Sepetka et al. | Dec 2009 | A1 |
20100004726 | Hancock et al. | Jan 2010 | A1 |
20100023048 | Mach | Jan 2010 | A1 |
20100023105 | Levy et al. | Jan 2010 | A1 |
20100030200 | Strauss et al. | Feb 2010 | A1 |
20100042133 | Ramzipoor et al. | Feb 2010 | A1 |
20100069948 | Veznedaroglu et al. | Mar 2010 | A1 |
20100087908 | Hilaire et al. | Apr 2010 | A1 |
20100094335 | Gerberding et al. | Apr 2010 | A1 |
20100131002 | Connor et al. | May 2010 | A1 |
20100152767 | Greenhalgh et al. | Jun 2010 | A1 |
20100185271 | Zhang | Jul 2010 | A1 |
20100222802 | Gillespie, Jr. et al. | Sep 2010 | A1 |
20100268260 | Riina et al. | Oct 2010 | A1 |
20100274276 | Chow et al. | Oct 2010 | A1 |
20100312270 | McGuckin, Jr. et al. | Dec 2010 | A1 |
20100331948 | Turovskiy et al. | Dec 2010 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110054519 | Neuss | Mar 2011 | A1 |
20110082493 | Samson et al. | Apr 2011 | A1 |
20110106234 | Grandt | May 2011 | A1 |
20110144669 | Becking et al. | Jun 2011 | A1 |
20110152993 | Marchand et al. | Jun 2011 | A1 |
20110184452 | Huynh et al. | Jul 2011 | A1 |
20110184453 | Levy et al. | Jul 2011 | A1 |
20110196415 | Ujiie et al. | Aug 2011 | A1 |
20110202085 | Loganathan et al. | Aug 2011 | A1 |
20110208227 | Becking | Aug 2011 | A1 |
20110245862 | Dieck et al. | Oct 2011 | A1 |
20110265943 | Rosqueta et al. | Nov 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110313447 | Strauss et al. | Dec 2011 | A1 |
20110319926 | Becking et al. | Dec 2011 | A1 |
20120041470 | Shrivastava et al. | Feb 2012 | A1 |
20120065720 | Strauss et al. | Mar 2012 | A1 |
20120101561 | Porter | Apr 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120143317 | Cam et al. | Jun 2012 | A1 |
20120165803 | Bencini et al. | Jun 2012 | A1 |
20120165919 | Cox et al. | Jun 2012 | A1 |
20120197283 | Marchand et al. | Aug 2012 | A1 |
20120245674 | Molaei et al. | Sep 2012 | A1 |
20120245675 | Molaei et al. | Sep 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120316598 | Becking et al. | Dec 2012 | A1 |
20120330341 | Becking et al. | Dec 2012 | A1 |
20120330347 | Becking et al. | Dec 2012 | A1 |
20130018451 | Grabowski et al. | Jan 2013 | A1 |
20130066357 | Aboytes et al. | Mar 2013 | A1 |
20130066360 | Becking et al. | Mar 2013 | A1 |
20130085522 | Becking et al. | Apr 2013 | A1 |
20130092013 | Thompson et al. | Apr 2013 | A1 |
20130123830 | Becking et al. | May 2013 | A1 |
20130211495 | Halden et al. | Aug 2013 | A1 |
20130233160 | Marchand et al. | Sep 2013 | A1 |
20130239790 | Thompson et al. | Sep 2013 | A1 |
20130245667 | Marchand et al. | Sep 2013 | A1 |
20130268053 | Molaei et al. | Oct 2013 | A1 |
20130274862 | Cox et al. | Oct 2013 | A1 |
20130274863 | Cox et al. | Oct 2013 | A1 |
20130274866 | Cox et al. | Oct 2013 | A1 |
20130274868 | Cox et al. | Oct 2013 | A1 |
20130304179 | Bialas et al. | Nov 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140005713 | Bowman | Jan 2014 | A1 |
Number | Date | Country |
---|---|---|
2607529 | Apr 2008 | CA |
101472537 | Jul 2009 | CN |
1283434 | Nov 1968 | DE |
102008028308 | Apr 2009 | DE |
102011011510 | Aug 2012 | DE |
775470 | May 1997 | EP |
855170 | Jul 1998 | EP |
1621148 | Feb 2006 | EP |
1637176 | Mar 2006 | EP |
1752112 | Feb 2007 | EP |
1942972 | Jul 2008 | EP |
1872742 | May 2009 | EP |
2157937 | Mar 2010 | EP |
2279023 | Feb 2011 | EP |
2363075 | Sep 2011 | EP |
2496299 | Sep 2012 | EP |
2675402 | Dec 2013 | EP |
2556210 | Apr 1988 | FR |
2890306 | Mar 2007 | FR |
11-506686 | Jun 1999 | JP |
2003520103 | Jul 2003 | JP |
2003-524434 | Aug 2003 | JP |
2004-049585 | Feb 2004 | JP |
2005-522266 | Jul 2005 | JP |
2006-506201 | Feb 2006 | JP |
2008-541832 | Nov 2008 | JP |
4673987 | Apr 2011 | JP |
WO-8800813 | Feb 1988 | WO |
WO-9601591 | Jan 1996 | WO |
WO-9726939 | Jul 1997 | WO |
WO-9903404 | Jan 1999 | WO |
WO 9905977 | Feb 1999 | WO |
WO-9908607 | Feb 1999 | WO |
WO 9908743 | Feb 1999 | WO |
WO-9962432 | Dec 1999 | WO |
WO 0193782 | Dec 2001 | WO |
WO 0200139 | Jan 2002 | WO |
WO-02071977 | Sep 2002 | WO |
WO-2005117718 | Dec 2005 | WO |
WO-2006026744 | Mar 2006 | WO |
WO-2006034166 | Mar 2006 | WO |
WO-2006052322 | May 2006 | WO |
WO-2006091891 | Aug 2006 | WO |
WO-2006119422 | Nov 2006 | WO |
WO-2007047851 | Apr 2007 | WO |
WO 2007076480 | Jul 2007 | WO |
WO-2007121405 | Oct 2007 | WO |
WO 2008022327 | Feb 2008 | WO |
WO 2008051294 | May 2008 | WO |
WO 2008151204 | Dec 2008 | WO |
WO-2008157507 | Dec 2008 | WO |
WO 2009076515 | Jun 2009 | WO |
WO-2009132045 | Oct 2009 | WO |
WO-2009134337 | Nov 2009 | WO |
WO-2009135166 | Nov 2009 | WO |
WO-2010028314 | Mar 2010 | WO |
WO-2010030991 | Mar 2010 | WO |
WO-2011057277 | May 2011 | WO |
WO-2011130081 | Oct 2011 | WO |
WO-2011153304 | Dec 2011 | WO |
Entry |
---|
International Search Report and Written Opinion dated Apr. 12, 2011 for International Application No. PCT/US 11/23054. |
International Search Report and Written Opinion for International Application No. PCT/US2009/051316, mailed on Nov. 23, 2009, in 17 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2009/051316; dated Jan. 25, 2011. |
Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2009/051316; dated Feb. 3, 2011. |
International Search Report and Written Opinion dated May 5, 2011 in International Application No. PCT/US 11/23058. |
Hill, et al., “Initial Results of the Amplatzer Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004. |
Ronnen, “Amplatzer Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007. |
U.S. Appl. No. 13/669,652, filed Nov. 6, 2012. |
U.S. Appl. No. 13/629,678, filed Sep. 28, 2012. |
U.S. Appl. No. 13/826,298, filed Mar. 14, 2013. |
U.S. Appl. No. 13/795,556, filed Mar. 12, 2013. |
U.S. Appl. No. 13/962,267, filed Aug. 8, 2013. |
Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040. |
Number | Date | Country | |
---|---|---|---|
20100023105 A1 | Jan 2010 | US |
Number | Date | Country | |
---|---|---|---|
61082579 | Jul 2008 | US |